Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02649790 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications
A Phase 1 study, sponsored by Karyopharm Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 277
- Enrollment target
NCT02649790 is a Phase 1 study that has completed, run by Karyopharm Therapeutics. The registered enrollment target is 277 participants.
The verdict
NCT02649790, a Phase 1 study, has completed, sponsored by Karyopharm Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 277 participants
- Enrollment target
Study Summary
This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple myeloma (MM), metastatic colorectal cancer (mCRC), metastatic castration resistant prostate cancer (mCRPC), higher risk myelodysplastic syndrome (HRMDS), acute myeloid leukemia (AML) and newly diagnosed intermediate/high-risk MDS. Dose escalation and dose expansion may be included for all parts of the study as determined by ongoing study results.
Interventions
- DRUG Dexamethasone
- DRUG ASTX727
- DRUG KPT-8602
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2016-01 |
| Est. Completion | 2024-12-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02649790
The ClinicalTrials.gov registry entry for NCT02649790 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Karyopharm Therapeutics, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Dexamethasone is the first listed.
NCT02649790 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02649790 about?
NCT02649790 is a clinical study titled "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications". This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in participants with relapsed/refractory multiple my...
What is the current status of trial NCT02649790?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 277 participants. The study started on 2016-01. Estimated completion is 2024-12-23.
What interventions are being tested in trial NCT02649790?
The interventions under investigation include: Dexamethasone (DRUG), ASTX727 (DRUG), KPT-8602 (DRUG).
Who is sponsoring clinical trial NCT02649790?
This trial is sponsored by Karyopharm Therapeutics, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.